These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6347107)

  • 1. Generation of prostacyclin stimulating activity in C6-deficient rabbit serum.
    Rampart M; Bult H; Herman AG
    Arch Int Pharmacodyn Ther; 1983 Apr; 262(2):326-9. PubMed ID: 6347107
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated complement and anaphylatoxins increase the in vitro production of prostacyclin by rabbit aorta endothelium.
    Rampart M; Bult H; Herman AG
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Mar; 322(2):158-65. PubMed ID: 6346110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells.
    Bult H; Coene MC; Rampart M; Herman AG
    Agents Actions Suppl; 1984; 14():237-47. PubMed ID: 6382974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
    Strunk RC; Giclas PC
    J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
    [No Abstract]   [Full Text] [Related]  

  • 5. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonspecific activation of complement factor 5 by isolated Dermacentor andersoni salivary antigens.
    Gordon JR; Allen JR
    J Parasitol; 1991 Apr; 77(2):296-301. PubMed ID: 2010863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of C3 and C5 prolongs cardiac xenograft survival and decreases leukocyte infiltration in a model of delayed xenograft rejection.
    Johnson EM; Leventhal J; Dalmasso AP; Goswitz J; Simone P; Chen S; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):603. PubMed ID: 8623296
    [No Abstract]   [Full Text] [Related]  

  • 8. Inactivation of complement by mouse saliva: enzymatic degradation of C2, C3, C4, C5, and C7.
    Weill JC; Leca G; Girard JF; Ayed K
    Clin Immunol Immunopathol; 1979 Apr; 12(4):425-35. PubMed ID: 455793
    [No Abstract]   [Full Text] [Related]  

  • 9. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.
    Ruseva MM; Hughes TR; Donev RM; Sivasankar B; Pickering MC; Wu X; Harris CL; Morgan BP
    Mol Immunol; 2009 Feb; 46(5):803-11. PubMed ID: 18947875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent bacterial meningitis in patients with genetic defects of terminal complement components.
    Haeney MR; Thompson RA; Faulkner J; Mackintosh P; Ball AP
    Clin Exp Immunol; 1980 Apr; 40(1):16-24. PubMed ID: 7389212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts.
    Brauer RB; Baldwin WM; Daha MR; Pruitt SK; Sanfilippo F
    J Immunol; 1993 Dec; 151(12):7240-8. PubMed ID: 8258722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.
    Pierangeli SS; Girardi G; Vega-Ostertag M; Liu X; Espinola RG; Salmon J
    Arthritis Rheum; 2005 Jul; 52(7):2120-4. PubMed ID: 15986360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.
    Hoover DL; Berger M; Hammer CH; Meltzer MS
    J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the reaction of the sixth component of rabbit complement.
    Rother U; Till G; Thumb R
    Z Immunitatsforsch Exp Klin Immunol; 1973 Dec; 146(3):260-73. PubMed ID: 4282979
    [No Abstract]   [Full Text] [Related]  

  • 17. C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes.
    Van den Berg CW; Hazenberg MA; Hofhuis FM; Van Rooyen SM; Van Dijk H
    Immunology; 1991 Jul; 73(3):264-70. PubMed ID: 1879875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement function and disorders.
    Kehoe JM
    Pediatr Ann; 1976 Jun; 5(6):397-404. PubMed ID: 1272620
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fifth component of complement (C5): purification without activation.
    Dessauer A; Rother U
    Immunobiology; 1983 May; 164(5):370-9. PubMed ID: 6347874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.